Skip to main content
main-content

04-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The KEYNOTE-146/Study 111 trial

Chung-Han Lee reports the final analysis of KEYNOTE-146/Study 111 trial of lenvatinib plus pembrolizumab in metastatic clear-cell renal cell carcinoma after immune checkpoint inhibitor therapy (4:57).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Read transcript

Have your say on Medicine Matters

Visit the conference hub

Image Credits